HER2-Positive Metastatic Breast Cancer: The Treatment Shift Reshaping the Market
A Decade of Reinvention There was a time when a HER2-positive breast cancer diagnosis carried a particularly difficult outlook. The biology was aggressive, treatment options were limited, and metasta ...
A Budget Impact Analysis Payers Can Trust: The Thelansis Framework
How the Thelansis budget impact modeling framework turns a payer's first and most literal question, "What will this cost my budget next year?" into a forecast a client can act on and a payer can indep ...
Beyond Market Size: How Patient, Epidemiology & Competitive Intelligence Can Shape Oncology Investment Strategies
Background: A biopharmaceutical company was evaluating the investment potential of a targeted oncology asset. Initial market assessments appeared attractive. The indication had a sizable patient popu ...
Evidence Without Context: Why Advanced Analytics Still Miss Commercial Reality
Advanced analytics has transformed how life sciences teams generate evidence. We can analyze massive datasets, model future markets, and simulate treatment pathways with remarkable precision. Yet desp ...
Defining a Differentiated Target Product Profile (TPP) to Win in a Crowded Therapy Area
Background: The client was advancing a Phase II biologic in a chronic inflammatory disease category already dense with competition. While early clinical data showed encouraging efficacy and a managea ...
Beyond GLP-1s: Inside Obesity’s $80 Billion Second Wave
The first wave of obesity innovation proved a simple point: meaningful weight loss can be delivered at scale if patients can start therapy, stay on it, and afford it. GLP-1s turned obesity into one of ...
ESMO 2026 Preview: What the Abstracts Reveal Before the Data Drops
Every major oncology congress has its headline moments: a trial that changes practice, a therapy that exceeds expectations, or a new mechanism that suddenly becomes the industry's next big focus.But E ...
How Patient Journey Analytics Improves Drug Commercialization
A drug's clinical trial data tells you how it performs under ideal conditions. It doesn't tell you where your patients actually are, why they're taking three years to get diagnosed, which physicians a ...
Clinical Differentiation Is No Longer Enough: How “Access Differentiation” Is Becoming the Real Moat
A therapy can post best-in-class trial data and still stall at launch. Not because the science was wrong, but because nobody could tell a payer what happens after the trial ends, when the drug meets r ...
Can Premium Pricing Survive in Rare Diseases? What 2026 Signals Say
For nearly two decades, rare diseases have lived in a pricing exception zone. Small patient populations, high unmet need, limited competition, and outcomes that could genuinely change a patient's life ...